The decrease in circulation levels of inflammatory mediators such as monocyte chemoattractant protein 1 (MCP-1) and resistin, as well as the increase in adiponectin levels in obese mice, is likely to be managed by luteolin's beneficial effects on metabolic pathways implicated in insulin resistance and DM pathogenesis [89]. This evidence concerns the gene CCL2 and Insulin resistance.